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N-acetylglucosamine (GlcNAc), the monomer of chitin and constituent 
of bacterial peptidoglycan, is a preferred 
carbon and nitrogen source for strepto-
mycetes. Recent studies have revealed 
new functions of GlcNAc in nutrient sig-
naling of bacteria. Exposure to GlcNAc 
activates development and antibiotic pro-
duction of Streptomyces coelicolor under 
poor growth conditions (famine) and 
blocks these processes under rich condi-
tions (feast). Glucosamine-6-phosphate 
(GlcN-6P) is a key molecule in this sig-
naling pathway and acts as an allosteric 
effector of a pleiotropic transcriptional 
repressor DasR, the regulon of which 
includes the GlcNAc metabolic enzymes 
N -acet y lg lucosamine-6 -phosphate 
(GlcNAc-6P) deacetylase (NagA) 
and GlcN-6P deaminase (NagB). 
Intracellular accumulation of GlcNAc-6P 
and GlcN-6P enhanced production of 
the pigmented antibiotic actinorhodin. 
When the nagB mutant was challenged 
with GlcNAc or GlcN, spontaneous 
second-site mutations that relieved the 
toxicity of the accumulated sugar phos-
phates were obtained. Surprisingly, dele-
tion of nagA also relieved toxicity of 
GlcN, indicating novel linkage between 
the GlcN and GlcNAc utilization path-
ways. The strongly enhanced antibiotic 
production observed for many suppressor 
mutants shows the potential of the mod-
ulation of GlcNAc and GlcN metabolism 
as a metabolic engineering tool toward 
the improvement of antibiotic produc-
tivity or even the discovery of novel 
compounds.
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Introduction
The alarming emergence of multiply anti-
biotic-resistant pathogens coupled with 
the lack of effective antimicrobials has 
revealed an urgent requirement for dis-
covery of new antibiotics. Streptomycetes 
are Gram-positive, soil-dwelling bacteria 
that have a complex life cycle that starts 
with the germination of a spore, which 
then grows out to form a branched veg-
etative mycelium. When morphological 
differentiation is initiated, a so-called 
aerial mycelium is produced, followed 
by the formation of long chains of unig-
enomic spores.1,2 Streptomycetes are best 
known for their ability to produce a broad 
range of secondary metabolites, including 
around 50% of all known antibiotics, as 
well as many antifungal, anticancer and 
immunosuppressant agents.3 The control 
of antibiotic production is complex, with 
typically many different transcriptional 
regulators dictating the expression of a 
single gene cluster, allowing the producing 
organism to correctly time biosynthesis, 
for example in response to growth phase 
or nutrient availability.4,5
As saprophytic soil bacteria, streptomy-
cetes are able to grow on a wide range of 
organic compounds due to production of 
numerous extracellular enzymes, such as 
amylases, cellulases, chitinases, proteases 
and lipases. Since organic matter is also a 
predominant source of nutrition for other 
microorganisms, bacteria had to develop 
mechanism of predation leading to elimi-
nation of competing organisms. It is sug-
gested that in natural habitat of bacteria, 
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master regulator DasR, whose regulon 
includes genes for GlcNAc transport and 
metabolism as well as antibiotic produc-
tion. A key molecule in this signaling cas-
cade is GlcN-6P, which acts as an allosteric 
effector of DasR and therefore prevents its 
DNA binding ability.15 This results in the 
relief of transcriptional repression of the 
pathway-specific regulatory genes for anti-
biotic production, including actII-ORF4 
and redZ, the pathway-specific activa-
tor genes for actinorhodin and prodigi-
nine biosynthesis, respectively. DasR also 
represses the cpk gene cluster for the cryp-
tic polyketide Cpk, although this interac-
tion may be mediated via the control of 
scbA and scbR,5 which encode the synthe-
tase for the γ-butyrolactone Scb1 and the 
Scb1-responsive transcriptional activator 
for Cpk biosynthesis, respectively.16,17 The 
molecular mechanism of GlcNAc signal-
ing under rich nutritional conditions, 
which results in the blockage of sporu-
lation and antibiotic production, is still 
unknown.
Role of GlcNAc in Control of  
Development and Antibiotic  
Production
N-acetylglucosamine (GlcNAc), the 
monomer or chitin and constituent of 
peptidoglycan, and the related amino 
acid glutamate are preferred nutrients as 
they serve as highly favorable carbon and 
nitrogen sources for streptomycetes.12,13 
Besides as nutrient, GlcNAc also serves 
as a signaling molecule in streptomyce-
tes. Accumulation of GlcNAc around the 
colonies at higher concentrations controls 
both morphological differentiation (spor-
ulation) and antibiotic production; under 
poor nutritional conditions (famine) the 
accumulation of GlcNAc promotes devel-
opment and antibiotic production, while 
under rich growth conditions (feast) these 
processes are inhibited.14 We previously 
proposed a complete signaling cascade 
from GlcNAc uptake to the onset of anti-
biotic production under famine condi-
tions. This pathway is transmitted via the 
this mechanisms is stimulated by produc-
tion of antibiotics leading to thwart of 
growth of competing organisms.3
Sequencing of the genomes of many 
Streptomyces and other actinomycetes 
revealed that most likely all filamentous 
actinomycetes possess a large arsenal of 
secondary metabolites, and only part of 
these are produced under standard labo-
ratory conditions.6 Therefore, novel strat-
egies not only for the improvement of 
antibiotic production, but also to wake 
up sleeping (also referred to as silent or 
cryptic) biosynthetic clusters are required 
to harness this potential. Current meth-
ods and technological advances regarding 
the discovery of new antibiotics have been 
reviewed elsewhere.7-9 Such approaches 
include engineering primary metabolism 
and regulatory cascades controlling anti-
biotic production.8,10,11
Figure 1. Glucose and aminosugar metabolism in S. coelicolor, with connecting pathways. annotation is based on the KeGG database31 and experi-
mental evidence. arrows shows the direction of metabolism, and the responsible enzymes are presented in bold face. See text for further details.
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is obtained with regard to the flux of 
GlcNAc and related metabolites, and how 
this influences the global regulatory routes 
that control Streptomyces development 
and antibiotic production. In the absence 
of nagA, addition of GlcNAc results in 
the accumulation of GlcNAc-6P, while 
in nagB mutants GlcN-6P accumulates 
(Fig. 1). nagA deletion mutants showed 
strongly enhanced production of the 
blue-pigmented antibiotic actinorhodin 
in the presence of GlcNAc, on both rich 
(R2YE) and poor (MM) solid media.21 
The likely accumulation of GlcN-6P 
in nagB mutants led to a strong increase 
in Act production on R2YE agar plates 
supplemented with GlcNAc, while the 
mutant failed to grow on MM agar plates 
supplemented with either GlcNAc or its 
deacetylated form, glucosamine (GlcN) 
(ref. 21 and Fig. 2). Toxicity of GlcN-6P 
was reported previously in Escherichia 
coli.26-28 In line with the idea that the accu-
mulation of GlcN-6P was the cause of the 
toxicity, nagAB double mutants (which do 
not accumulate GlcN-6P for the lack of 
NagA activity; Fig. 1) were able to grow 
on GlcNAc, but the enhanced antibiotic 
production remained (Fig. 2). However, 
we could not immediately explain the sur-
prising observation that also the toxicity 
of GlcN to nagB mutants was relieved by 
additional deletion of nagA, as involve-
ment of NagA in GlcN metabolism was 
not anticipated (Fig. 2). This sheds new 
Interestingly, some Streptomyces 
species, including S. bingchenggensis, 
S. cattleya, and S. violaceusniger, do not 
have a nagB ortholog. Genome mining 
revealed the presence of an open reading 
frame, which appears to be a hybrid of 
nagB/glmS2 and shows similarity to the 
nagB-II genes present in Gram-positive 
bacteria. These NagB-II homologs con-
tain the C-terminal domain of GlmS, 
but display only the catabolic activity of 
NagB.24,25 The fact that these three strep-
tomycetes also contain the PTS genes for 
internalization and phosphorylation of 
GlcNAc, including nagE2 (SBI_06686, 
SCATT_19300, Strvi_8260) and 
nagF (SBI_06687, SCATT_19290, 
Strvi_8259), as well as nagA (SBI_04956, 
SCAT_2457, Strvi_8764) for the sub-
sequent deacetylation of GlcNAc-6P to 
GlcN-6P, strongly suggests that indeed 
these organisms can catabolize GlcNAc 
using the NagB/GlmS2 hybrid enzyme 
instead of the canonical NagB.
Engineering of Aminosugar  
Metabolism as an Approach  
to Enhance Antibiotic Production
Better understanding of GlcNAc-
mediated signaling in streptomycetes 
requires the creation of multiple mutants, 
single and in combination, to block meta-
bolic routes so as to force the accumulation 
of specific metabolites. Thus new insight 
N-acetylglucosamine Metabolism
In S. coelicolor, the model organism of 
species, GlcNAc is transported via the 
phosphoenolpyruvate-dependent phos-
photransferase system (PTS).18,19 During 
PTS-mediated carbon source uptake, 
a phosphoryl group is transferred from 
phosphoenolpyruvate (PEP) to the general 
phosphotransferase enzyme I (EI; encoded 
by ptsI), from there to HPr (encoded by 
ptsH), and then further onto enzyme IIA 
(EIIACrr; encoded by crr) and enzyme IIB 
(e.g., NagF).12,20 NagF phosphorylates 
incoming via the permease IIC (NagE2) 
GlcNAc to form N-acetylglucosamine-
6-phosphate (GlcNAc-6P) (Fig. 1). Null 
mutants that have been constructed for 
any of the global PTS components (EI, 
EIIA, or HPr) locks streptomycetes in the 
vegetative growth phase.15
Recently we characterized the meta-
bolic enzymes in S. coelicolor, namely 
GlcNAc-6P deacetylase (NagA; 
SCO4284), GlcN-6P deaminase (NagB; 
SCO5236) and GlcNAc kinase (NagK; 
SCO4285).21 Similarly to the GlcNAc uti-
lization pathway of other bacteria, intracel-
lular GlcNAc-6P is deacetylated by NagA, 
which results in glucosamine-6-phosphate 
(GlcN-6P), the molecule which occupies 
a central position in the pathways toward 
cell-wall synthesis and glycolysis. GlcN-6P 
is converted by NagB to fructose-6-phos-
phate (Fru-6P), which enters the glyco-
lytic pathway,22,23 but is also incorporated 
into murein following its conversion to 
UDP-GlcNAc by the action of GlmM 
(phosphoglucosamine mutase) and GlmU 
(N-acetylglucosamine-1-phosphate uri-
dyltransferase) (Fig. 1). During growth 
on other carbon sources than amino-
sugars, GlcN-6P can be produced from 
Fru-6P by GlcN-6P synthase (glmS) 
(Fig. 1). NagK catalyzes the phosphoryla-
tion of intracellular GlcNAc to GlcNAc-6P 
(Fig. 1). In S. coelicolor, monomeric 
GlcNAc is transported via the PTS, 
resulting in intracellular GlcNAc-6P.12 
Intracellular unphosphorylated GlcNAc 
is most likely internalized as N-N’-
diacetylchitobiose [(GlcNAc)
2
] and/or 
other chito-oligosaccharides [(GlcNAc)
n
], 
such as those derived from chitin via the 
chitinolytic system.
Figure 2. Phenotypic analysis of nag mutants. Stereomicrographs showing the phenotypes of  
S. coelicolor M145, its nagB and nagAB mutants, nagB suppressor mutant SMG4 (obtained on Glcn) 
that has a deletion in nagA, and the complemented suppressor mutant expressing nagKA. Strains 
were grown for 5 days on MM agar plates supplemented with mannitol, Glcn or Glcnac. note that 
nagB mutants and complemented nagB suppressor mutants fail to grow (nG) on either amino-
sugar, while growth was restored to the nagAB double mutant and the nagB suppressor mutants, 
and also led to enhanced antibiotic overproduction.
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glucose, GlcN or GlcNAc. All strains devel-
oped normally on MM agar plates supple-
mented with mannitol (Fig. 3). However, 
three different phenotypes were observed 
for nagB suppressor mutants obtained in 
the presence of GlcNAc (Figs. 3 and 4). 
The first class of GlcNAc-selected nagB 
suppressor mutants displayed decreased 
antibiotic production but normal devel-
opment (SMA1; SMA4-SMA5). The two 
other classes showed enhanced antibiotic 
production and either blocked (SMA2-
SMA3; SMA6-SMA7; SMA9; SMA11-
SMA15) or normal development (SMA8 
and SMA10) (Figs. 3 and 4).
What happens when GlcN-obtained 
suppressor mutants are grown in the 
presence of GlcNAc or vice versa, when 
GlcNAc-obtained mutants are grown on 
GlcN-containing media? All suppressor 
mutants except one, were able to grow 
on both aminosugars. However, GlcN-
obtained nagB suppressor SMG1 is of 
particular interest, as it fails to grow on 
GlcNAc. This suggests that the second-site 
mutation specifically relieved the toxicity 
of GlcN and not of GlcNAc. Therefore, 
elucidation of this mutation would be of 
great interest for our understanding of 
GlcN(Ac) metabolism. A likely candi-
date is a mutation in the GlcN transport 
system, which so far has not been eluci-
dated. All other SMG strains overpro-
duced antibiotics, and for SMG2 and 
SMG3 development was blocked (Fig. 3). 
All GlcNAc-selected nagB suppressor 
mutants showed impaired development 
when grown on MM with GlcN, while 
some also displayed reduced antibiotic 
production (SMA1-SMA10) as compared 
with the wild-type strain (Figs. 3 and 4). 
Like for SMA suppressors, SMG mutants 
grown on MM agar plates supplemented 
with GlcNAc displayed three distinct 
phenotypes.
Interestingly, we also observed a strong 
effect of the inactivation of nagB and the 
subsequent suppressor mutants on anti-
biotic production on media not supple-
mented with GlcNAc or GlcN (Fig. 3). 
The nagB mutant and most of the suppres-
sor mutants obtained from either GlcNAc 
or GlcN showed enhanced antibiotic 
production and strong delay in aerial 
mycelium formation on MM agar plates 
supplemented with glucose. Glucose is 
phenotypes were obtained for suppressor 
mutants allowing growth in the presence 
of GlcNAc restreaked on MM + GlcNAc, 
while suppressor mutants with restored 
growth in the presence of GlcN had simi-
lar phenotypes on MM+GlcN. This sug-
gests that suppressor mutations may have 
arisen in different genes.
Fifteen suppressor mutants obtained 
on GlcNAc, designated SMA1-SMA15 
(Suppressor Mutants isolated on GlcNAc) 
and five independent suppressor mutants 
obtained on GlcN-containing media, 
SMG1-SMG5 (Suppressor Mutant iso-
lated on GlcN), were re-streaked on MM 
agar plates supplemented with mannitol, 
light on GlcN metabolism and suggests 
direct involvement of NagA in, or linkage 
between, both pathways.
When nagB mutant spores were plated 
at high density onto MM agar plates con-
taining either GlcNAc or GlcN, suppres-
sor mutants were readily obtained, with 
a frequency of around 1:105, which cor-
responds to expected single mutations or 
indels (insertions or deletions). This is a 
logical consequence of the fact that single 
mutations in for example nagA or any of 
the transporter genes should suffice to 
circumvent the accumulation of GlcN-6P 
as the likely cause for the observed toxic-
ity. Reproducibly at least three different 
Figure 3. analysis of antibiotic production by nagB suppressor mutants. Phenotypes of nagB 
suppressor mutants originally selected on Glcnac (1–15; corresponding to SMa1-SMa15) or Glcn 
(16–20; corresponding to SMG1-SMG5). the parental strain M145 (21) and the nagB mutant (22) 
were used as controls. Strains were grown on MM agar plates supplemented with mannitol, glu-
cose, Glcn or Glcnac. note that the nagB mutant failed to grow on MM supplemented with either 
aminosugar. Both front and reverse (inserts) of the agar plates are shown.
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of GlcN and GlcNAc metabolism is cur-
rently in progress.
Since only three out of the 19 GlcNAc-
selected nagB suppressor mutants were due 
to a second-site mutation in nagA, the 16 
remaining mutants most likely sustained 
a mutation in one or more other genomic 
loci that could also relieve aminosugar 
toxicity of nagB mutants. We are cur-
rently analyzing the genomes of several 
of the nagB suppressors. Identification of 
these mutations and the corresponding 
genes will shed new light on aminosugar 
metabolism in streptomycetes. These 
molecules play an important role in cen-
tral metabolism and cell-wall biosynthesis 
and accumulation of GlcN(Ac)-derived 
metabolites serves as a trigger of antibi-
otic production. Better understanding of 
aminosugar metabolism in streptomyce-
tes may provide alternative tools for the 
improvement of antibiotic productivity as 
well as the possible activation and discov-
ery of new antibacterial compounds.
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enhanced antibiotic production (Fig. 2). 
To establish if other suppressor mutants 
had also sustained a mutation or indel in 
nagA, 19 additional suppressor mutants 
obtained on GlcNAc and 15 obtained on 
GlcN were selected and complemented 
with a wild-type copy of the nagA gene. 
Of the transformants, 10 GlcN-selected 
and three GlcNAc-selected nagB suppres-
sor mutants lost their ability to grow in the 
presence of either aminosugar, suggesting 
they may also have been mutated in nagA.
The high frequency of second-site 
nagA mutations relieving GlcN toxic-
ity to nagB mutants strongly suggests 
that NagA is somehow involved in the 
conversion of internalized GlcN into the 
toxic compound GlcN-6P, or a deriva-
tive thereof, thus revealing a novel and 
unexpected intersection between the 
GlcN and GlcNAc utilization pathways in 
S. coelicolor. Up to date there are no 
reports presenting the involvement of the 
enzyme NagA in GlcN metabolism, nor 
is there any evidence of conversion of 
GlcN to the NagA substrate GlcNAc-6P 
(see KEGG database31). This presents 
one example of the high relevance of the 
suppressor mutants, and closer analysis 
transported to the cell via the GlcP per-
mease and enters glycolysis after subse-
quent phosphorylation by glucose kinase 
(Glk), respectively29 (Fig. 1). Glucose-6P 
can enter glycolysis or be converted in 
two steps into GlcN-6P, mediated via 
glucose-6P isomerase and GlmS (Fig. 1). 
Accumulation of part of the glucose as 
GlcN-6P may explain the effect of glucose 
on antibiotic production in the mutants.
Genetic Analysis of the nagB  
Suppressor Mutants Reveals  
Unsuspected Involvement  
of NagA in GlcN Utilization
Likely candidates for the suppressor 
mutations obtained on GlcNAc were the 
GlcNAc transporter genes nagE2 and 
nagF or the metabolic genes nagA or nagK. 
These genes and nagE1, a direct homo-
log and neighboring gene of nagE2, were 
amplified by PCR and subjected to DNA 
sequencing. In total 10 individual sup-
pressor mutants obtained on GlcN and 10 
obtained on GlcNAc were analyzed. While 
GlcNAc suppressors did not reveal muta-
tions in any of the sequenced genes or their 
promoter regions, one of nagB suppressor 
mutants selected on GlcN (SMG4) con-
tained an out-of-frame deletion of 416 bp 
in nagA (nt positions 261–676). In a con-
trol experiment, this suppressor mutant 
was complemented with plasmid pHJL401 
harboring the nagKA operon under the 
control of its own promoter. pHJL401 is 
a low-copy number vector which is very 
suitable for complementation experiments 
due to its stability and low copy number.30 
Indeed, this transformant had regained 
sensitivity to both GlcN or GlcNAc, indi-
cating that the deletion in nagA was the 
sole cause of the suppressor phenotype 
(Fig. 2). Full complementation of SMG4 
was also achieved with pHJL401 harbor-
ing only nagA under the control of the 
nagKA promoter (not shown).
In line with the idea that the accumu-
lation of GlcN-6P was the cause of the 
toxicity, nagAB double mutants (which 
do not accumulate GlcN-6P for the lack 
of NagA activity) grew well regardless of 
whether they were challenged with GlcN or 
GlcNAc. Moreover, the mutants displayed 
Figure 4. Phenotypic diversity of nagB suppressor mutants. Stereomicrographs illustrating the 
phenotypes of S. coelicolor M145 and representatives of three different classes of SMa mutants 
(SMa1, SMa8, SMa11) and of SMG mutants (SMG1-SMG3) grown on MM agar plates supplemented 
with Glcn (M145 and SMG mutants; left) or Glcnac (M145 and SMa mutants; right). colonies were 
grown for 5 days. note that the majority of nagB suppressor mutants overproduce antibiotics.
©
20
12
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
www.landesbioscience.com Bioengineered 285
22. Plumbridge J, Vimr E. Convergent pathways for 
utilization of the amino sugars N-acetylglucosamine, 
N-acetylmannosamine, and N-acetylneuraminic acid 
by Escherichia coli. J Bacteriol 1999; 181:47-54; 
PMID:9864311.
23. Vogler AP, Lengeler JW. Analysis of the nag regulon 
from Escherichia coli K12 and Klebsiella pneumoniae 
and of its regulation. Mol Gen Genet 1989; 219:97-
105; PMID:2693951; http://dx.doi.org/10.1007/
BF00261163.
24. Teplyakov A, Obmolova G, Badet-Denisot MA, 
Badet B. The mechanism of sugar phosphate isomeri-
zation by glucosamine 6-phosphate synthase. Protein 
Sci 1999; 8:596-602; PMID:10091662; http://
dx.doi.org/10.1110/ps.8.3.596.
25. Yang C, Rodionov DA, Li X, Laikova ON, Gelfand 
MS, Zagnitko OP, et al. Comparative genomics and 
experimental characterization of N-acetylglucosamine 
utilization pathway of Shewanella oneidensis. J Biol 
Chem 2006; 281:29872-85; PMID:16857666; 
http://dx.doi.org/10.1074/jbc.M605052200.
26. Bernheim NJ, Dobrogosz WJ. Amino sugar sensi-
tivity in Escherichia coli mutants unable to grow on 
N-acetylglucosamine. J Bacteriol 1970; 101:384-91; 
PMID:4905307.
27. Plumbridge J. An alternative route for recycling of 
N-acetylglucosamine from peptidoglycan involves 
the N-acetylglucosamine phosphotransferase sys-
tem in Escherichia coli. J Bacteriol 2009; 191:5641-
7; PMID:19617367; http://dx.doi.org/10.1128/
JB.00448-09.
28. White RJ. Control of amino sugar metabolism in 
Escherichia coli and isolation of mutants unable to 
degrade amino sugars. Biochem J 1968; 106:847-58; 
PMID:4866432.
29. van Wezel GP, Mahr K, König M, Traag BA, 
Pimentel-Schmitt EF, Willimek A, et al. GlcP consti-
tutes the major glucose uptake system of Streptomyces 
coelicolor A3(2). Mol Microbiol 2005; 55:624-36; 
PMID:15659175; http://dx.doi.org/10.1111/j.1365-
2958.2004.04413.x.
30. van Wezel GP, White J, Hoogvliet G, Bibb MJ. 
Application of redD, the transcriptional activator 
gene of the undecylprodigiosin biosynthetic path-
way, as a reporter for transcriptional activity in 
Streptomyces coelicolor A3(2) and Streptomyces livi-
dans. J Mol Microbiol Biotechnol 2000; 2:551-6; 
PMID:11075931.
31. Kyoto Encyclopedia of Genes and Genomes (KEGG) 
Database [Internet]. 1995 - .Release 63.0. Kyoto 
(Japan): Kanehisa Laboratories. [updated 2012 
July 1; cited 2012 July 5]. Available from: http://
ww w.genome.jp /kegg-bin/show_pathway?org_
name=sco&mapno=00520.
13. van Wezel GP, Krabben P, Traag BA, Keijser BJ, 
Kerste R, Vijgenboom E, et al. Unlocking Streptomyces 
spp. for use as sustainable industrial production plat-
forms by morphological engineering. Appl Environ 
Microbiol 2006; 72:5283-8; PMID:16885277; 
http://dx.doi.org/10.1128/AEM.00808-06.
14. Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae 
AW, Hopwood DA, et al. Feast or famine: the global 
regulator DasR links nutrient stress to antibiotic pro-
duction by Streptomyces. EMBO Rep 2008; 9:670-
5; PMID:18511939; http://dx.doi.org/10.1038/
embor.2008.83.
15. Rigali S, Nothaft H, Noens EE, Schlicht M, Colson 
S, Müller M, et al. The sugar phosphotransfer-
ase system of Streptomyces coelicolor is regulat-
ed by the GntR-family regulator DasR and links 
N-acetylglucosamine metabolism to the control of 
development. Mol Microbiol 2006; 61:1237-51; 
PMID:16925557; http://dx.doi.org/10.1111/j.1365-
2958.2006.05319.x.
16. D’Alia D, Eggle D, Nieselt K, Hu WS, Breitling 
R, Takano E. Deletion of the signalling molecule 
synthase ScbA has pleiotropic effects on second-
ary metabolite biosynthesis, morphological differ-
entiation and primary metabolism in Streptomyces 
coelicolor A3(2). Microb Biotechnol 2011; 4:239-51; 
PMID:21342469; http://dx.doi.org/10.1111/j.1751-
7915.2010.00232.x.
17. Hsiao NH, Söding J, Linke D, Lange C, Hertweck C, 
Wohlleben W, et al. ScbA from Streptomyces coelicolor 
A3(2) has homology to fatty acid synthases and is able 
to synthesize gamma-butyrolactones. Microbiology 
2007; 153:1394-404; PMID:17464053; http://
dx.doi.org/10.1099/mic.0.2006/004432-0.
18. Brückner R, Titgemeyer F. Carbon catabolite repres-
sion in bacteria: choice of the carbon source and 
autoregulatory limitation of sugar utilization. FEMS 
Microbiol Lett 2002; 209:141-8; PMID:12007797; 
http://dx.doi.org/10.1016/S0378-1097(02)00559-1.
19. Nothaft H, Dresel D, Willimek A, Mahr K, 
Niederweis M, Titgemeyer F. The phosphotrans-
ferase system of Streptomyces coelicolor is biased 
for N-acetylglucosamine metabolism. J Bacteriol 
2003; 185:7019-23; PMID:14617669; http://dx.doi.
org/10.1128/JB.185.23.7019-7023.2003.
20. Nothaft H, Dresel D, Willimek A, Mahr K, 
Niederweis M, Titgemeyer F. The phosphotrans-
ferase system of Streptomyces coelicolor is biased 
for N-acetylglucosamine metabolism. J Bacteriol 
2003; 185:7019-23; PMID:14617669; http://dx.doi.
org/10.1128/JB.185.23.7019-7023.2003.
21. Swiatek MA, Tenconi E, Rigali S, van Wezel GP. 
Functional analysis of the N-acetylglucosamine met-
abolic genes of Streptomyces coelicolor and role in 
control of development and antibiotic production. 
J Bacteriol 2012; 194:1136-44; PMID:22194457; 
http://dx.doi.org/10.1128/JB.06370-11.
References
1. Chater KF, Losick R. Mycelial life style of Streptomyces 
coelicolor A3(2) and its relatives. In: Shapiro JA, 
Dworkin M, eds. Bacteria as multicellular organisms. 
New York: Oxford University Press, 1997:149-82.
2. Flärdh K, Buttner MJ. Streptomyces morphogenetics: 
dissecting differentiation in a filamentous bacterium. 
Nat Rev Microbiol 2009; 7:36-49; PMID:19079351; 
http://dx.doi.org/10.1038/nrmicro1968.
3. Hopwood DA. Streptomyces in nature and medicine: 
the antibiotic makers. New York: Oxford University 
Press, 2007.
4. Sánchez S, Chávez A, Forero A, García-Huante Y, 
Romero A, Sánchez M, et al. Carbon source regula-
tion of antibiotic production. J Antibiot (Tokyo) 
2010; 63:442-59; PMID:20664603; http://dx.doi.
org/10.1038/ja.2010.78.
5. van Wezel GP, McDowall KJ. The regulation of the 
secondary metabolism of Streptomyces: new links and 
experimental advances. Nat Prod Rep 2011; 28:1311-
33; PMID:21611665; http://dx.doi.org/10.1039/
c1np00003a.
6. Challis GL, Hopwood DA. Synergy and contingency 
as driving forces for the evolution of multiple second-
ary metabolite production by Streptomyces species. 
Proc Natl Acad Sci U S A 2003; 100(Suppl 2):14555-
61; PMID:12970466; http://dx.doi.org/10.1073/
pnas.1934677100.
7. Baltz RH. Renaissance in antibacterial discovery from 
actinomycetes. Curr Opin Pharmacol 2008; 8:557-
63; PMID:18524678; http://dx.doi.org/10.1016/j.
coph.2008.04.008.
8. Martín JF, Liras P. Engineering of regulatory cascades 
and networks controlling antibiotic biosynthesis in 
Streptomyces. Curr Opin Microbiol 2010; 13:263-
73; PMID:20303823; http://dx.doi.org/10.1016/j.
mib.2010.02.008.
9. van Wezel GP, McKenzie NL, Nodwell JR. Chapter 
5. Applying the genetics of secondary metabolism 
in model actinomycetes to the discovery of new 
antibiotics. Methods Enzymol 2009; 458:117-41; 
PMID:19374981; http://dx.doi.org/10.1016/S0076-
6879(09)04805-8.
10. Butler MJ, Bruheim P, Jovetic S, Marinelli F, 
Postma PW, Bibb MJ. Engineering of primary car-
bon metabolism for improved antibiotic production 
in Streptomyces lividans. Appl Environ Microbiol 
2002; 68:4731-9; PMID:12324314; http://dx.doi.
org/10.1128/AEM.68.10.4731-4739.2002.
11. Chen Y, Smanski MJ, Shen B. Improvement of 
secondary metabolite production in Streptomyces by 
manipulating pathway regulation. Appl Microbiol 
Biotechnol 2010; 86:19-25; PMID:20091304; 
http://dx.doi.org/10.1007/s00253-009-2428-3.
12. Nothaft H, Rigali S, Boomsma B, Swiatek M, 
McDowall KJ, van Wezel GP, et al. The permease 
gene nagE2 is the key to N-acetylglucosamine sens-
ing and utilization in Streptomyces coelicolor and 
is subject to multi-level control. Mol Microbiol 
2010; 75:1133-44; PMID:20487300; http://dx.doi.
org/10.1111/j.1365-2958.2009.07020.x.
